跳至主要内容
临床试验/NCT06122948
NCT06122948已完成3 期

Effect of Intranasal Midazolam Versus Ketamine Midazolam Combination as a Premedication in Children Undergoing Tonsillectomy and Adenoidectomy on the Occurrence of Postoperative Respiratory Adverse Events: a Double-blind, Randomized Controlled Trial

Kasr El Aini Hospital1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2023年11月4日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
200
试验地点
1
主要终点
The incidence of any perioperative respiratory adverse events (PRAEs)

研究概览

简要总结

The aim of this study is to investigate the effect of addition of intranasal ketamine to midazolam compared to midazolam alone as a premedication on the occurrence of PRAEs

详细描述

Perioperative respiratory adverse events (PRAEs) are the most common complication during pediatric anesthesia furthermore, most children presenting for AT have sleep-disordered breathing and obstructive sleep apnea syndrome (OSAS) caused by tonsillar hypertrophy which could aggravate the PRAEs specially with the use of the conventional sedatives as a premedication. A recent randomized controlled trial has shown that more than 50% of children premedicated with midazolam had experienced PRAEs . Midazolam and ketamine are commonly used as preoperative sedative drugs for pediatric populations. Ketamine is a safe and widely used sedative and analgesic in the pediatric emergency department (ED) with less profound effects on the upper airway and respiratory muscles. Intranasal ketamine administration is well tolerated and without serious adverse effects. The addition of ketamine to midazolam as a preoperative sedation to reduce the occurrence of PRAEs was not investigated before in children undergoing AT. The authors hypothesize that combination of ketamine to midazolam could offer optimum sedation condition while reducing the occurrence of PRAEs in children undergoing AT.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

The drug will be prepared by an anesthesia nurse who will not be involved in the study. The active drug will be administered by a fully trained anesthesiologist and Clear definitions of the respiratory adverse events will be provided to the involved anesthetist. All researchers directly involved in the study will be blinded to the drug which will be administered

入排标准

年龄范围
3 Years 至 12 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Children both sexes male and female.
  • Age from 3 to 12 years old.
  • ASA grade I, II.
  • undergoing elective AT procedures.

排除标准

  • Congenital heart diseases (cyanotic and a cyanotic).
  • Congenital syndromes affecting airway anatomy such as Pierre-Robin syndrome and Down syndrome.
  • Severe lung diseases affecting either lung tissue such as pulmonary cystic fibrosis and idiopathic pulmonary fibrosis or affecting lung circulation such as pulmonary hypertension with marked limitation of Physical activity or inability to carry out any physical activity according to NHYA classification.
  • Recent upper respiratory tract infection (less than two weeks).
  • Neuromuscular diseases including cerebral palsy and epilepsy.

研究组 & 干预措施

(Group M)

Active Comparator

The midazolam group will receive intranasal midazolam (0.1 mg/kg)

干预措施: The midazolam group (Drug)

(Group MK)

Experimental

Midazolam ketamine group will receive intranasal midazolam (0.1mg/kg) and ketamine (3mg/kg)

干预措施: The midazolam ketamine group (Drug)

结局指标

主要结局

The incidence of any perioperative respiratory adverse events (PRAEs)

时间窗: 8 hours

the incidence of any PRAEs (Perioperative respiratory adverse events (PRAEs) which are manifested as minor (oxygen desaturation (SaO2 less than 95% for 10 seconds) or coughing) and major as (bronchospasm, laryngospasm, airway obstruction, stridor or hypoxia (oxygen desaturation less than 90%)) among midazolam versus midazolam ketamine groups.

次要结局

  • Postoperative pain score(8 hours)
  • Sedation success rate(8 hours)
  • Postoperative emergence delirium(8 hours)

研究者

发起方
Kasr El Aini Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Khaled Abdelfattah Abdallah Sarhan

principal investigator, Asst. professor of anesthesia, Cairo university

Kasr El Aini Hospital

研究点 (1)

Loading locations...

相似试验